Cytosorbents Corporation (CTSO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cytosorbents Corporation (CTSO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.03

-0.01 (-0.96%)

At close: Jan 15, 2025, 9:47 AM

undefined% (undefined)

Bid	1
Market Cap	56.48M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.36
PE Ratio (ttm)	-2.86
Forward PE	n/a
Analyst	Buy

Ask	1.03
Volume	30,023
Avg. Volume (20D)	274,193
Open	1.06
Previous Close	1.04
Day's Range	1.00 - 1.09
52-Week Range	0.70 - 1.59
Beta	undefined

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complication...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Aug 8, 2006

Employees 186

Stock Exchange NASDAQ

Ticker Symbol CTSO

Website https://www.cytosorbents.com

Analyst Forecast

According to 4 analyst ratings, the average rating for CTSO stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 531.07% from the latest price.

Buy 50.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Cytosorbents Corporation is scheduled to release its earnings on Mar 6, 2025, after market closes.
Analysts project revenue of $9.43M, reflecting a 8.39% YoY growth and earnings per share of -0.07, making a -41.67% decrease YoY.

Why Price Moved

3 months ago · Source

-10%

CytoSorbents shares are trading lower. The company... Unlock content with Pro Subscription

5 months ago · Source

+17.48%

Cytosorbents shares are trading higher after EF Hutton initiated coverage on the stock with a Buy rating and announced a price target of $10.

News

2 months ago · seekingalpha.com

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Confer...